Product approval information is indicated for children and adults with hemophilia A (congenital factor VIII deficiency) for: (1) On-demand treatment and control of bleeding episodes; (2) Perioperative management; (3) Routine prophylaxis to reduce the frequency of bleeding episodes.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2nh3mDZ
No comments:
Post a Comment